Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Schistosoma mansoni | Thioredoxin glutathione reductase | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | thioredoxin reductase | 0.0046 | 0.2529 | 1 |
Brugia malayi | Thioredoxin reductase | 0.0046 | 0.2529 | 0.7809 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0116 | 0.7738 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0016 | 0.0312 | 0.5 |
Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.0104 | 0.6874 | 0.8837 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0116 | 0.7738 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.3238 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0116 | 0.7738 | 1 |
Mycobacterium tuberculosis | Probable dehydrogenase | 0.0104 | 0.6874 | 0.8837 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0046 | 0.2574 | 0.773 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.3238 | 1 |
Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.0104 | 0.6874 | 0.8837 |
Treponema pallidum | NADH oxidase | 0.0016 | 0.0312 | 0.5 |
Brugia malayi | dihydrolipoyl dehydrogenase, mitochondrial precursor, putative | 0.0016 | 0.0312 | 0.0963 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.3238 | 0.3021 |
Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.0104 | 0.6874 | 0.8837 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0016 | 0.0312 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.3238 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0016 | 0.0312 | 0.5 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0016 | 0.0312 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.3238 | 1 |
Plasmodium falciparum | thioredoxin reductase | 0.0046 | 0.2529 | 1 |
Trypanosoma brucei | trypanothione reductase | 0.0046 | 0.2529 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0016 | 0.0312 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.3238 | 0.3021 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0046 | 0.2529 | 0.2985 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0016 | 0.0312 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.3238 | 1 |
Brugia malayi | glutathione reductase | 0.0046 | 0.2529 | 0.7809 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0016 | 0.0312 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.3238 | 0.3021 |
Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.0104 | 0.6874 | 0.8837 |
Leishmania major | trypanothione reductase | 0.0046 | 0.2529 | 1 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.3238 | 1 |
Plasmodium vivax | glutathione reductase, putative | 0.0046 | 0.2529 | 1 |
Plasmodium falciparum | glutathione reductase | 0.0046 | 0.2529 | 1 |
Mycobacterium tuberculosis | Probable reductase | 0.0104 | 0.6874 | 0.8837 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0016 | 0.0312 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0016 | 0.0312 | 0.5 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0046 | 0.2574 | 0.773 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0046 | 0.2529 | 1 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0046 | 0.2529 | 1 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0116 | 0.7738 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 3.1623 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 8.9125 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.